201 related articles for article (PubMed ID: 28220706)
1. Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.
Zhou H; Peng Y; Halikhedkar A; Fan P; Janero DR; Thakur GA; Mercier RW; Sun X; Ma X; Makriyannis A
ACS Chem Neurosci; 2017 Jun; 8(6):1338-1347. PubMed ID: 28220706
[TBL] [Abstract][Full Text] [Related]
2. Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation.
Szymanski DW; Papanastasiou M; Melchior K; Zvonok N; Mercier RW; Janero DR; Thakur GA; Cha S; Wu B; Karger B; Makriyannis A
J Proteome Res; 2011 Oct; 10(10):4789-98. PubMed ID: 21861534
[TBL] [Abstract][Full Text] [Related]
3. Binding Site Characterization of AM1336, a Novel Covalent Inverse Agonist at Human Cannabinoid 2 Receptor, Using Mass Spectrometric Analysis.
Mallipeddi S; Kreimer S; Zvonok N; Vemuri K; Karger BL; Ivanov AR; Makriyannis A
J Proteome Res; 2017 Jul; 16(7):2419-2428. PubMed ID: 28374590
[TBL] [Abstract][Full Text] [Related]
4. Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor.
Janero DR; Yaddanapudi S; Zvonok N; Subramanian KV; Shukla VG; Stahl E; Zhou L; Hurst D; Wager-Miller J; Bohn LM; Reggio PH; Mackie K; Makriyannis A
ACS Chem Neurosci; 2015 Aug; 6(8):1400-10. PubMed ID: 25978068
[TBL] [Abstract][Full Text] [Related]
5. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
Janero DR; Korde A; Makriyannis A
Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
[TBL] [Abstract][Full Text] [Related]
6. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.
Laprairie RB; Kulkarni AR; Kulkarni PM; Hurst DP; Lynch D; Reggio PH; Janero DR; Pertwee RG; Stevenson LA; Kelly ME; Denovan-Wright EM; Thakur GA
ACS Chem Neurosci; 2016 Jun; 7(6):776-98. PubMed ID: 27046127
[TBL] [Abstract][Full Text] [Related]
7. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
Pandey P; Roy KK; Doerksen RJ
J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
[TBL] [Abstract][Full Text] [Related]
8. Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction.
Shim JY; Welsh WJ; Howlett AC
Biopolymers; 2003; 71(2):169-89. PubMed ID: 12767117
[TBL] [Abstract][Full Text] [Related]
9. Aliphatic Azides as Selective Cysteine Labeling Reagents for Integral Membrane Proteins.
Szymanski D; Papanastasiou M; Pandarinathan L; Zvonok N; Janero DR; Pavlopoulos S; Vouros P; Makriyannis A
J Med Chem; 2018 Dec; 61(24):11199-11208. PubMed ID: 30444608
[TBL] [Abstract][Full Text] [Related]
10. (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor.
Picone RP; Khanolkar AD; Xu W; Ayotte LA; Thakur GA; Hurst DP; Abood ME; Reggio PH; Fournier DJ; Makriyannis A
Mol Pharmacol; 2005 Dec; 68(6):1623-35. PubMed ID: 16157695
[TBL] [Abstract][Full Text] [Related]
11. Residues accessible in the binding-site crevice of transmembrane helix 6 of the CB2 cannabinoid receptor.
Nebane NM; Hurst DP; Carrasquer CA; Qiao Z; Reggio PH; Song ZH
Biochemistry; 2008 Dec; 47(52):13811-21. PubMed ID: 19053233
[TBL] [Abstract][Full Text] [Related]
12. Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template.
Zhang R; Hurst DP; Barnett-Norris J; Reggio PH; Song ZH
Mol Pharmacol; 2005 Jul; 68(1):69-83. PubMed ID: 15840841
[TBL] [Abstract][Full Text] [Related]
13. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.
Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM
Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271
[TBL] [Abstract][Full Text] [Related]
14. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.
Ragusa G; Gómez-Cañas M; Morales P; Rodríguez-Cueto C; Pazos MR; Asproni B; Cichero E; Fossa P; Pinna GA; Jagerovic N; Fernández-Ruiz J; Murineddu G
Eur J Med Chem; 2017 Feb; 127():398-412. PubMed ID: 28088085
[TBL] [Abstract][Full Text] [Related]
15.
Gianquinto E; Sodano F; Rolando B; Kostrzewa M; Allarà M; Mahmoud AM; Kumar P; Spyrakis F; Ligresti A; Chegaev K
Molecules; 2022 Nov; 27(23):. PubMed ID: 36500256
[TBL] [Abstract][Full Text] [Related]
16. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.
Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968
[TBL] [Abstract][Full Text] [Related]
17. Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists.
Jiang S; Iliopoulos-Tsoutsouvas C; Tong F; Brust CA; Keenan CM; Raghav JG; Hua T; Wu S; Ho JH; Wu Y; Grim TW; Zvonok N; Thakur GA; Liu ZJ; Sharkey KA; Bohn LM; Nikas SP; Makriyannis A
J Med Chem; 2021 Apr; 64(7):3870-3884. PubMed ID: 33761251
[TBL] [Abstract][Full Text] [Related]
18. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.
McAllister SD; Rizvi G; Anavi-Goffer S; Hurst DP; Barnett-Norris J; Lynch DL; Reggio PH; Abood ME
J Med Chem; 2003 Nov; 46(24):5139-52. PubMed ID: 14613317
[TBL] [Abstract][Full Text] [Related]
19. A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor.
Hurst DP; Grossfield A; Lynch DL; Feller S; Romo TD; Gawrisch K; Pitman MC; Reggio PH
J Biol Chem; 2010 Jun; 285(23):17954-64. PubMed ID: 20220143
[TBL] [Abstract][Full Text] [Related]
20. New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists.
Faúndez-Parraguez M; Alarcón-Miranda C; Cho YH; Pessoa-Mahana H; Gallardo-Garrido C; Chung H; Faúndez M; Pessoa-Mahana D
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
